All Releases |
|---|
 |
XOMA Reports 2009 and Fourth Quarter Financial Results
Mar 11, 2010
|
21.9 KB
|
| |
BERKELEY, Calif., Mar 11, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the full year and fourth quarter of 2009 and provided a general business update.
XOMA had total revenues of $98.4 million in 2009, compa...
|
|
|
XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11
Mar 4, 2010
|
10.4 KB
|
| |
BERKELEY, Calif., Mar 4, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a conference call and webcast on Thursday, March 11, 2010 at 4:30 pm Eastern time to discuss 2009 and fourth quarter financial results and provide ...
|
|
|
XOMA to Webcast Presentations From Two March 2010 Investment Conferences
Feb 25, 2010
|
10.2 KB
|
| |
BERKELEY, Calif., Feb 25, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that company management will participate in two investment conferences in March 2010. Steven B. Engle, Chairman and Chief Executive Officer, will participate in a panel disc...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
Feb 9, 2010
|
11.6 KB
|
| |
BERKELEY, Calif., Feb 9, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate, XOMA 052, in Type 2 diabetes patients. The randomized, placebo-c...
|
|
|
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
Feb 3, 2010
|
10.3 KB
|
| |
BERKELEY, Calif., Feb 3, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Steven B. Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the 12th annual BIO CEO and Investor Conference on Tuesday, February 9, 2009 at...
|
|
|
XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants
Feb 2, 2010
|
11.3 KB
|
| |
BERKELEY, Calif., Feb 2, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the pricing of an underwritten offering of 42 million units at a price to investors of $0.50 per unit for gross proceeds of approximately $21.0 million. After underwri...
|
|
|
XOMA Reviews Priorities for 2010 and 2009 Accomplishments
Jan 19, 2010
|
15.4 KB
|
| |
BERKELEY, Calif., Jan 19, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a summary of its priorities for 2010 and accomplishments during 2009.
"In 2009, we continued to advance our lead product candidate, XOMA 052, an antibody to interl...
|
|
|
XOMA Reports Removal of "Going Concern" Qualification
Dec 22, 2009
|
10.3 KB
|
| |
BERKELEY, Calif., Dec 22, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that, as a result of an improvement in the Company's financial status and in particular its full repayment of an outstanding loan, at the Company's request, its indep...
|
|
|
XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference
Dec 10, 2009
|
11.2 KB
|
| |
BERKELEY, Calif., Dec 10, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, reported results demonstrating the advantages of its monoclonal antibody technologies in the rapid development of a first-in-class multiple antibody product candidate, XOMA 3AB. XOMA...
|
|
|
XOMA Announces NASDAQ Matter Resolved With Letter of Reprimand
Dec 9, 2009
|
8.9 KB
|
| |
BERKELEY, Calif., Dec 9, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a Letter of Reprimand from the staff of The NASDAQ Stock Market LLC on December 8, 2009 for non-compliance with NASDAQ's Listing Rule 5635(d)(2) in connecti...
|
|
|
XOMA Receives NASDAQ Determination Letter
Nov 19, 2009
|
9.0 KB
|
| |
BERKELEY, Calif., Nov 19, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced...
|
|
|
XOMA Appoints Jim Neal Vice President of Business Development
Nov 17, 2009
|
11.0 KB
|
| |
BERKELEY, Calif., Nov 17, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to exe...
|
|
|
XOMA 052 Selected as a Top Ten Project to Watch
Nov 12, 2009
|
11.0 KB
|
| |
BERKELEY, Calif., Nov 12, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced its anti-inflammatory antibody to interleukin-1 beta (IL-1 beta), XOMA 052, has been selected as a Top Ten Cardiovascular/metabolic Project to Watch for partnering opportuni...
|
|
|
XOMA Announces Presentation at Lazard Healthcare Conference on November 18
Nov 11, 2009
|
10.5 KB
|
| |
BERKELEY, Calif., Nov 11, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer of XOMA, is scheduled to present at the 6th annual Lazard Healthcare Conference on Wednesday, November 18, at 1...
|
|
|
XOMA Reports 2009 Third Quarter Financial Results
Nov 9, 2009
|
26.7 KB
|
| |
BERKELEY, Calif., Nov 9, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter and nine months ended September 30, 2009 and provided a general business update. XOMA has made significant progress in 2009...
|
|
|
XOMA Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
Nov 6, 2009
|
14.6 KB
|
| |
BERKELEY, Calif., Nov 6, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits an...
|
|
|
Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
Nov 4, 2009
|
14.4 KB
|
| |
BERKELEY, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced plans to initiate an investigator sponsored Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. The trial ...
|
|
|
XOMA Granted First European Patent Covering XOMA 052
Nov 4, 2009
|
10.4 KB
|
| |
BERKELEY, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the grant of its first European Patent related to the XOMA 052 program. Granted by the European Patent Office, the patent covers XOMA's interleukin-1 beta (IL-1 beta) ...
|
|
|
XOMA to Announce Third Quarter 2009 Financial Results and Host Conference Call on November 9
Nov 3, 2009
|
10.7 KB
|
| |
BERKELEY, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a conference call and webcast on Monday, November 9 at 9:00 a.m. Eastern time to discuss third quarter 2009 financial results and provide a general...
|
|
|
XOMA Signs Antibody Discovery Collaboration With Kaketsuken
Nov 3, 2009
|
10.9 KB
|
| |
BERKELEY, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems. ...
|
|
|
$0.01
